P1, top 200, grp 2 Word Scramble
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Brand | Generic | Class | Indication | Dose Form | Route | Adult Dose | Pediatric Dose | MOA |
Aciphex | Rabeprazole | PPI (proton pump inhibitor) | GERD, Duodenal Ulcer Disease | Tablet: 20 mg | Oral | 20-60 mg QD-BID | 12 years and older: 20 mg once daily for 8 weeks.1 1 to 11 years: 15 kg or more: 10 mg once daily for up to 12 weeks. Less than 15 kg: 5 mg once daily for up to 12 weeks; increase to 10 mg if inadequate response | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Nexium | esomeprazole | PPI (proton pump inhibitor) | GERD, Duodenal Ulcer Disease, Gastric Ulcer | Delayed-release caps: 20 or 40 mg Delayed-release powder for susp: 2.5, 5, 10, 20, 40 mg Powder for inj: 20 or 40 mg | Oral, injection | 20-40 mg QD | 1 MO -1 YO: 0.5mg/kg QD 1-17 YO: 10-20 mg QD for 8 weeks | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Prevacid | lansoprazole | PPI (proton pump inhibitor) | Duodenal Ulcer Disease, Gastric ULcer, Esophagitis, GERD | Tablets or Solutabs: 15-30 mg | Oral | 15-30 mg QD | 1-12YO: <30kg15mg;>30kg 30mg QD | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Prilosec | omeprazole | PPI (proton pump inhibitor) | GERD, Duodenal Ulcer Disease, Stress Ulcer, Gastric Ulcer, Esophagitis | Delayed-release Granules for susp: 2.5 or 10 mg Delayed-release Caps: 10, 20, 40 mg Delayed-release OTC Tab: 20 mg | Oral | 20-40 mg QD | 5-20 mg QD | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Protonix | pantoprazole | PPI (proton pump inhibitor) | GERD, Gastric Hypersecretion | Delayed-release Tab: 20-40 mg Delayed-release granules for susp: 40 mg Powder for Inj: 40 mg | Oral, IV | 40-80 mg QD-BID | >5YO:<40kg-20mg; >40kg-40mg QD | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Dexilant | dexlansoprazole | PPI (proton pump inhibitor) | Esophagitis, GERD, Pyrosis (heartburn) | Delayed-relase capsule: 30 or 60 mg | Oral | 30-60 mg QD | N/A | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Welchol | Colesevelam | Bile Acid Sequesterant | Hypercholesterolemia, Hyperlipoproteinemia, Type 2 Diabetes Mellitus | Tablet: 625mg Powder for Susp: 3.75mg | Oral | 3 tabs BID or 6 tabs QD; 1.875 gram packet BID or 3.75 gram packet QD | 10-17 YO: 1.875 gram single-dose packet BID or 3.75 gram packet QD (Not for under 10 yrs) | Binds with bile acids in the intestine to form an insoluble complex that is eliminated in the feces |
Zantac | Ranitidine | Histamine, H2 antagonist | GERD, Duodenal Ulcer Disease, Gastric Ulcer, Indigestion | Syrup: 75mg/5ml or 150mg/10ml Tablets: 75, 150, 300mg Inj. Soln.: 1mg/ml or 25mg/ml Granules for Soln.: 150mg Effervescent Tab: 25 or 150mg | Oral, IV | Oral: 150mg QD-BID IV: 50mg Q6-8 hrs | 2-4 mg/kg/day (oral or IV) | Competitive reversible inhibitor of histamine at H2 receptors |
Zetia | Ezetimibe | Cholesterol Absorption Inhibitor | Hypercholesterolemia, Hyperlipoproteinemia | Tablets: 10mg | Oral | 10mg QD | 10 YO+: 10mg QD | Inhibits absorption of cholesterol at the brush border of the small intestine via the sterol transporter NPC1L1 |
Niaspan | Niacin | Nicotinic Acid | Hyperlipidemia | ER Tablets: 500, 750, 1000mg | Oral | 100-1000mg TID (max of 4500mg/day) | 100-250mg QD (divided into 3 doses) | Precise MOA unknown |
Pepcid | Famotidine | Histamine H2 Antagonist | Duodenal Ulcer, Dyspepsia, Esophagitis, Gastric Ulcer, GERD, H. Pylori Eradication, Multiple Endocrine Adenoma Syndrome, Pyrosis, Systemic Mastocytosis, Zollinger-Ellison Syndrome | Tablets: 20 or 40mg; AC 10mg tablet or gelcap Premixed Inj. Soln.: 10mg/ml, 20mg/50ml Powder For Susp: 40mg/5ml Complete Chew Tab | Oral, IV | 20-160mg QD or BID | 0-16YO: 0.5mg/kg QD or BID | Inhibits the binding of histamine to H2 receptors on the gastric basolateral membrane of parietal cells, reducing basal and nocturnal gastric acid secretions |
Tricor | Fenofibrate | Antilipemic Agent, Fibric Acid | Hypercholesterolemia, hypertriglyceridema | Tablet: 48mg, 145mg | Oral | Hypertriglyceridemia: 48-145mg QD Hypercholesterolemia or mixed dysplipidemia: 145mg QD | safety not established | Agonist of nuclear transcription factor PPar-alpha |
Vytorin | Ezetimibe/Simvastatin | Antilipemic Agent, HMG-CoA Reductase Inhibitor | Hypercholesterolemia, Hyperlipidemia, ASCVD | Tablet: 10mg, 20mg, 40mg, 80mg | Oral | 10-40 mg po qd | 10yrs+ 10-20 mg po qd | sterol transporter inhibitor, HMG-CoA Reductase inhibitor |
Lipitor | Atorvastatin | HMG-CoA Reductase Inhibitor | Hypercholeserolemia & mixed hyperlipidemia, ASCVD | Tablet: 10mg, 20mg, 40mg, 80mg | Oral | 10-80 mg qd | HeHF: 10-17yr(females>1 yr postmenarche): 10mg qd. Max 20mg | HMG-CoA Reductase inhibitor |
Lovaza | Omega-3 ethyl esters | Acyl-CoA Inhibitor | Hypertriglyceridemia | Soft gel Capsule: 1g=1000mg | Oral | 4g qd or 2g bid | N/A | Acyl-CoA Inhibitor |
Mevacor | Lovastatin | Antilipemic agent, HMG-CoA Reductase Inhibitor | Dyslipidemia & 1o prevent of CAD (coronary artery disease), ASCVD | Tablet: 10, 20, 40mg | Oral | 20mg qd w/ evening meal. Max 80mg ASCVD: 40mg qd | Heterozygous familial hypercholesterolemia: 10-17yr LDL reduction <20%: 10 qd w/ evening meal LDL reduction ≥ 20%: 20 qd w/ evening meal Max: 40 mg | HMG-CoA Reductase Inhibitor |
Crestor | Rosuvastatin | HMG-CoA Inhibitor | Hyperlipidemia,Hypertriglyceridemia, Atherosclerosis,Hyperlipoproeteinemia,Hypercholesterolemia,Prophylaxis | Tablets:5,10,20,40 mg | oral | 5-40mg QD | 10-17YO:5-20mg QD | HMG-CoA Reductase inhibitor |
Pravachol | Pravastatin | HMG-CoA Inhibitor | Hyperlipidemia, Hypercholesterolemia, Prophylaxis | Tablets: 10,20,40,80 | oral | 40-80mgQD | 8-13YO:20 mg QD 13-18YO: 40mg QD | HMG-CoA Reductase inhibitor |
Trilipix | Choline Fenofibrate | Antilipemic Agent, Fibric Acid | Hypercholesterolemia, hypertriglyceridema | Capsule Delayed release 45mg and 135mg | Oral | Hypertriglyceridemia: 45-135mg QD Hypercholesterolemia or mixed dysplipidemia: 135mg QD | Safety and efficacy in children have not been established | Agonist of nuclear transcription factor PPar-alpha |
Antara | Fenofibrate | Antilipemic Agent, Fibric Acid | Hypercholesterolemia, hypertriglyceridema | Capsule: 30,90 mg | Oral | Hypertriglyceridemia: 30-90mg QD Hypercholesterolemia or mixed dysplipidemia: 90mg QD | Safety and efficacy in children have not been established | Agonist of nuclear transcription factor PPar-alpha |
Zocor | Simvastatin | HMG-CoA Inhibitor | Heterozygous familial hypercholesterolemia in adolescents (10 to 17 years of age, Hyperlipidemia, Primary and secondary prevention of atherosclerotic cardiovascular disease | Tablet: 5,10,20,40,80mg | Oral | Hyperlipidemia: 5 to 40 mg QD in the evening. Homozygous familial hypercholesterolemia: 40 mg QD in the evening, Prevention of coronary events: 5 to 40 mg QD in the evening | Heterozygous familial hypercholesterolemia: 10 to 17 years of age: 10 to 40 mg QD | HMG-CoA Reductase inhibitor |
Zofran | Ondansetron | Serotonin Receptor Antagonist, 5-HT3 (Antiemetic) | Prevention of nausea and vomiting due to chemo, or post op, or radiotherapy | Tablet Dispersible: 4,8mg Film: 4,8mg | Oral | Cancer,Highly Emetogenic: 24mg 30min before, Moderate Emetogenic: 8mg Bid start 30 before. Radiotherapy: 8mg TID start 1-2 before. Post op: 16mg 1hr prior to anesthesia | Only approved for moderately emetogenic <12 years of age: 8mg BID start 30 min before. 4-11 years of age: 8mg BID start 30 min before. | Serotonin Receptor Antagonist, 5-HT3 (Antiemetic) |
Created by:
Ryan Stocks
Popular Pharmacology sets